CORCEPT THERAPEUTICS INC — Form 10-Q
Filed July 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Joseph K. Belanoff (CEO) and Atabak Mokari (CFO) certified the June 30, 2026 quarterly report on July 29, 2026 under SOX 302 and 906. Both officers affirm the financial statements fairly present results, disclosure controls are effective, and no material weaknesses or significant deficiencies in internal controls were identified. No specific financial data, transactions, or business changes are disclosed in these certification exhibits.
Why this rating
Routine SOX certifications with no disclosure of control weaknesses, fraud, or material changes. Boilerplate compliance document.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.